← Back to patent-cliff list
Naperiglipron
Tier C — Watch / tradeNaperiglipron
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R
Indications (approved)：Overweight, Obesity, Type 2 diabetes
Regional status
US
Phase II
2024-11-13
EU
Phase I
2022-05-09
China
Phase I
2025-05-25
Japan
Phase I
2025-05-07
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Naperiglipron?
Approved indications include: Overweight, Obesity, Type 2 diabetes.
When does the Naperiglipron patent expire?
No public expiry year is available for Naperiglipron yet; this page updates once verified.
How do I get a quote for Naperiglipron intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01